title: Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
abstract: Podocyte damage and accumulation of advanced glycation end products (AGEs) are characteristics of diabetic nephropathy (DN). The pathophysiology of AGE-challenged podocytes, such as hypertrophy, apoptosis, and reduced cell migration, is closely related to the induction of the cell cycle inhibitor p27(Kip1) and to the inhibition of neuropilin 1 (NRP1). We have previously demonstrated that treatment with erythropoietin is associated with protective effects for podocytes in vitro. db/db mice with overt DN aged 15-16 wk were treated with either placebo, epoetin-β, or continuous erythropoietin receptor activator (CERA) for 2 wk. db/db mice compared with nondiabetic db/m control mice revealed the expected increases in body weight, blood glucose, albumin-to-creatinine ratio, and AGE accumulation. Whereas there were no differences in body weight, hyperglycemia and AGEs were observed among diabetic mice that received epoetin-β compared with CERA and placebo treatment, indicating that epoetin-β/CERA treatment does not interfere with the development of diabetes in this model. However, the albumin-to-creatinine ratio was significantly lower in db/db mice treated with epoetin-β or CERA. Furthermore, kidney weights in db/db mice were increased compared with db/m control mice, indicating renal hypertrophy, whereas the increase in renal weight in epoetin-β- or CERA-treated db/db mice was significantly lower than in placebo-treated control mice. Induction of p27(Kip1) and suppression of NRP1 were significantly reduced in the epoetin-β treatment group versus the CERA treatment group. Furthermore, erythropoietin treatment diminished the diabetes-induced podocyte loss. Together, independently from hematopoetic effects, epoetin-β or CERA treatment was associated with protective changes in DN, especially that NRP1 and p27(Kip1) expressions as well as numbers of podocytes returned to normal levels. Our data show, for the first time, that medication of overt DN with erythropoietin for a short time can ameliorate albuminuria and podocyte loss.
authors.affiliation: Dept. of Internal Medicine III, Univ. Hospital Jena, Univ. of Jena, Erlanger Allee 101, Jena D-07740, Germany. Gunter.Wolf@med.uni-jena.de.
authors.forename: Ivonne
authors.initials: I
authors.lastname: Loeffler
authors.forename: Christiane
authors.initials: C
authors.lastname: Rüster
authors.forename: Sybille
authors.initials: S
authors.lastname: Franke
authors.forename: Marita
authors.initials: M
authors.lastname: Liebisch
authors.forename: Gunter
authors.initials: G
authors.lastname: Wolf
mesh_terms: D000419:Albuminuria / Q000517:prevention & control; D000818:Animals; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000096:biosynthesis; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D004921:Erythropoietin / Q000627:therapeutic use*; D017127:Glycation End Products, Advanced / Q000378:metabolism; D008297:Male; D051379:Mice; D039942:Neuropilin-1 / Q000037:antagonists & inhibitors; D050199:Podocytes / Q000187:drug effects / Q000502:physiology; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D017127:Glycation End Products, Advanced; D011994:Recombinant Proteins; C508420:continuous erythropoietin receptor activator; C103998:epoetin beta; D004921:Erythropoietin; D039942:Neuropilin-1; D050760:Cyclin-Dependent Kinase Inhibitor p27; D011092:Polyethylene Glycols
keywords: continuous erythropoietin receptor activator; db/db mouse; diabetic nephropathy; erythropoietin; podocytes